AC Immune COO discloses initial share holdings
AC Immune SA Chief Operating Officer Piergiorgio Donati filed an initial ownership report detailing his equity position.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AC Immune SA Chief Operating Officer Piergiorgio Donati filed an initial ownership report detailing his equity position. He directly holds 141,120 common shares, which include 136,620 common shares underlying outstanding restricted share units. In addition, he reports multiple share options over common shares with exercise prices between $2.03 and $9.50 per share and expiration dates from July 2028 through December 2035. Some options are already fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026, providing a staggered schedule of potential future share deliveries.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Footnotes (5)
- F1. Includes 136,620 common shares underlying outstanding restricted share units.
- F2. The share option is fully vested.
- F3. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2024.
- F4. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2025.
- F5. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the AC Immune (ACIU) Form 3 filing by Piergiorgio Donati show?
Are any of Piergiorgio Donati’s AC Immune (ACIU) options already vested?
When do Piergiorgio Donati’s AC Immune (ACIU) options begin vesting?
Does the AC Immune (ACIU) Form 3 show any recent buying or selling by Piergiorgio Donati?
AI-generated analysis. How Rhea-AI works. Not financial advice.
